Phosphorus Attached Indirectly To Amino Nitrogen By Nonionic Bonding Patents (Class 564/15)
  • Patent number: 9738668
    Abstract: Benzothiazole phosphonate analogs and methods of using the same to inhibit the activity of Amyloid Binding Alcohol Dehydrogenase and in the amelioration or treatment of Alzheimer's disease are provided.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: August 22, 2017
    Assignee: University of Kansas
    Inventors: ShiDu Yan, Koteswara Rao Valasani
  • Publication number: 20150147361
    Abstract: The invention relates to the use of sphingosine based compounds, in particular phytosphingosine compounds, in the protection of hydroxyapatite containing materials such as teeth and bone. Such compounds are especially useful in the treatment and prevention of dental caries, dental erosion, dentine hypersensitivity and tartar (dental calculus) formation. Methods and devices are also provided for preventing biofilm formation using sphingosine based compounds. Compositions comprising sphingosine based compounds are also provided.
    Type: Application
    Filed: April 26, 2013
    Publication date: May 28, 2015
    Applicant: Stichting VU-VUmc
    Inventors: Floris Jacob Bikker, Engelmundus Cornelis Ignatius Veerman, Marianne Valentijn-Benz, Willem Van'T Hof
  • Publication number: 20150137083
    Abstract: Conjugated aromatic derivatives having an electron donating group and an electron accepting group at each end are provided. The conjugated aromatic derivatives of the present invention may be provided with blue light-emitting property and may be applied as a host material, a dopant material, an electron transporting material or a hole transporting material. An OLED device using the conjugated aromatic derivatives is also herein disclosed.
    Type: Application
    Filed: April 16, 2014
    Publication date: May 21, 2015
    Applicant: National Tsing Hua University
    Inventors: Chien-Hong CHENG, Chih-Chun LIN
  • Publication number: 20150133688
    Abstract: New compounds which meet general formula (I): where: m=0, 1 or 2; R1 and R2=a C6 to C12, straight-chain or branched, hydrocarbon group; R3=H, a C1 to C12, straight-chain or branched, hydrocarbon group, optionally comprising one or more heteroatoms; a C3 to C8 monocyclic hydrocarbon group, optionally comprising one or more heteroatoms, or a monocyclic (hetero)aryl group; or else R2 and R3 together form a —(CH2)n— group where n=1 to 4; R4=a C2 to C8, straight-chain or branched, hydrocarbon group, or a monocyclic aromatic group; R5=H, or a C1 to C12, straight-chain or branched, hydrocarbon group.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 14, 2015
    Applicant: AREVA Mines
    Inventors: Guilhem Arrachart, Nicolas Aychet, Gilles Bernier, Fabien Burdet, Antoine Leydier, Manuel Miguirditchian, Stephane Pellet-Rostaing, Gabriel Plancque, Raphael Turgis, Elisabeth Zekri
  • Publication number: 20150105296
    Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using hydroxy-sphingomyelin SM-OH-22:1 as biomarker.
    Type: Application
    Filed: September 19, 2014
    Publication date: April 16, 2015
    Inventors: Sebastiano Collino, Ivan Montoliu Roura, Francois-Pierre Martin, Philippe Alexandre Guy, Serge Andre Dominique Rezzi
  • Publication number: 20150099165
    Abstract: The invention relates to an electrolyte for a lithium-based energy storage device comprising at least one lithium salt, a solvent and at least one compound of general formula (1), and to their use in lithium-based energy storage devices.
    Type: Application
    Filed: October 31, 2012
    Publication date: April 9, 2015
    Inventors: Christian Dippel, Alexandra Lex-Balducci, Martin Winter, Miriam Kunze, René Schmitz, Romek Ansgar Müller, Stefano Passerini, Nataliya Kalinovich, Gerd-Volker Röschenthaler, Tobias Böttcher
  • Patent number: 8981126
    Abstract: Phosphenium compounds with the general formula I: in which R1, R2, R3 and R4 are identical or different and represent a linear or branched C1-C6-alkyl radical, which can optionally be substituted, or R1 and R2 and/or R3 and R4 are bonded to one another with the formation of a ring, R5 and R6 stand for a saturated or unsaturated and linear or branched alkyl group, alkenyl group or aryl group, which can have suitable substituents, even heteroatoms as substituents, or a heteroatom-comprising hydrocarbon group, which can have suitable substituents, and the R5 and R6 radicals can form a ring which can be 4- to 20-membered, saturated or unsaturated and alicyclic or heteroalicyclic and can exhibit suitable substituents, X? represents an anion, a process for the preparation thereof, and also the use of these compounds in metal complexes which can be used as catalysts in organic synthesis, are claimed.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: March 17, 2015
    Assignee: Studiengesellshaft Kohle mbH
    Inventors: Manuel Alcarazo, Hans Bruns, Jekaterina Petuskova
  • Publication number: 20150057253
    Abstract: The present invention relates to alkyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: August 20, 2014
    Publication date: February 26, 2015
    Inventors: Wenkui K. Fang, Ken Chow, Evelyn G. Corpuz
  • Publication number: 20150045328
    Abstract: The present invention relates to aryl oxy derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: August 6, 2014
    Publication date: February 12, 2015
    Inventors: Wenkui K. Fang, Ken Chow, Evelyn G. Corpuz
  • Publication number: 20150025026
    Abstract: Campylobacter are the commonest reported bacterial causes of gastroenteritis in the UK and industrialized worlds. This invention relates to a method of preventing or reducing the colonisation of the gastrointestinal tract of an animal with Campylobacter. Accordingly, the present invention provides a method for disinfection of an animal comprising administering to said animal at least one compound that binds to MOMP or FlaA of Campylobacter in an effective amount to reduce the number of Campylobacter present in the gastrointestinal tract of said animal. The present invention also provides a method of preventing or reducing transmission of Campylobacter from one animal to another.
    Type: Application
    Filed: February 15, 2013
    Publication date: January 22, 2015
    Inventors: Jafar Mahdavi, Dlawer Ala'Aldeen
  • Publication number: 20150005258
    Abstract: The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide containing at least one positively charged amino acid residue; each R1 is independently hydrogen, alkyl, or a phosphate group; R2 a linker; R3 is a spacer group; R4 is hydrogen, alkyl, aryl, or heterocyclic; or R4 and R1, or R4 and R3, together with the nitrogen atoms to which they are attached form a heterocyclic ring, and W is hydrogen or alkyl.
    Type: Application
    Filed: September 18, 2012
    Publication date: January 1, 2015
    Applicant: Genci Corporation
    Inventors: Shaharyar M. Khan, Robert Gadwood, Arthur Glenn Romero
  • Publication number: 20140319064
    Abstract: A preparation method of ethylenediamine core, octamethylenephosphonic acid terminated, PAMAM dendrimer and application thereof is provided, wherein terminal amino groups of ethylenediamine core, 0 generation, PAMAM dendrimer is modified by methylene phosphonic acid. The ethylenediamine core, octamethylenephosphonic acid terminated, PAMAM dendrimer has an excellent performance to inhibit scales of CaCO3, CaSO4 and Ca3(PO4)2, a very high calcium tolerance, and excellent dispersing performance. The ethylenediamine core, octamethylenephosphonic acid terminated, PAMAM dendrimer is used as an antiscalant in industrial water treatment, and is suitable for the industrial water treatment of boiler, cooling, desalination, and oil production, etc., especially for the industrial water treatment under high calcium concentration.
    Type: Application
    Filed: July 16, 2013
    Publication date: October 30, 2014
    Inventors: Fengting Li, Bingru Zhang, Hongtao Wang, Yinan Wu
  • Publication number: 20140312311
    Abstract: An optoelectronic materials for OLED is represented by formula (I): wherein R1 is selected from a group consisting of formulas (II)-(VI): wherein R2 and R3 are identical and selected from a group consisting of formula (VII) and formula (VIII): The optoelectronic materials possesses superior luminescent performance and thermal stability and is suitable to be a new type of ambipolar materials for OLED elements.
    Type: Application
    Filed: July 11, 2013
    Publication date: October 23, 2014
    Inventors: Chien-Tien CHEN, Wei-Shan CHAO, Hao-Wei LIU, Wei-Sheng SU
  • Publication number: 20140309422
    Abstract: The present invention relates to the compound of dialkyl(2-alkoxy-6-aminophenyl)phosphine and the preparation method thereof and the application in the palladium catalyzed coupling reactions of aryl chloride and ketone. The dialkyl(2-alkoxy-6-aminophenyl)phosphine of the present invention could coordinate with the palladium catalyst to highly selectively activate the inert carbon-chlorine bond, and to catalyze direct arylation reaction in the ?-position of ketones to produce corresponding coupling compounds. The preparation method of the present invention is a simple one-step method which produces the air-stable dialkyl(2-alkoxy-6-aminophenyl)phosphine. Compared with the synthetic routes of ligands to be used in the activation of carbon-chlorine bonds in the prior arts, the preparation method of the present invention has the advantages of short route and easy operation.
    Type: Application
    Filed: July 3, 2012
    Publication date: October 16, 2014
    Applicant: ZHEJIANG UNIVERSITY
    Inventors: Shengming Ma, Bo Lv, Chunling Fu
  • Patent number: 8859509
    Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: October 14, 2014
    Assignee: Yale University
    Inventors: David Spiegel, Ryan Murelli, Andrew Zhang
  • Patent number: 8846922
    Abstract: The present invention relates to functionalized fluoroalkylfluorophosphate salts, in particular as ionic liquids, to the preparation thereof and to the use thereof.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: September 30, 2014
    Assignee: Merck Patent GmbH
    Inventors: Berthold Theo Hoge, Anne Julia Bader, Nikolai Mykola Ignatyev, Michael Schulte, Wolfgang Hierse, Waldemar Wiebe, Helge Willner
  • Patent number: 8846645
    Abstract: The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, particularly for use as an antibiotic.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: September 30, 2014
    Assignees: Rheinische Friedrich-Wilhelms Universität Bonn, Universität Konstanz
    Inventors: Günter Mayer, Christina Elsbeth Luense, Valentin Wittmann, Magnus S. Schmidt
  • Publication number: 20140287640
    Abstract: Disclosure of functionalized ionic liquids. Use of disclosed ionic liquids as solvent for carbon dioxide. Use of disclosed ionic liquids as flame retardant. Use of disclosed ionic liquids for coating fabric to obtain flame retardant fabric.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Applicant: Materials Modification Inc
    Inventors: Humcha Krishnamurthy Hariprakasha, Krishnaswamy Kasthuri Rangan, Tirumalai Srinivas Sudarshan
  • Publication number: 20140249105
    Abstract: Compounds, ceramide analogues, having a cyclic structure derived from cyclopropane, cyclobutane or cyclopentane, the ring bearing two chains consisting of an amide function. Each amide function is attached to the ring by the nitrogen atom of the function and carries a hydrocarbon chain derived from a fatty acid. The amide functions can be cis or trans relative to one another. Processes for the preparation of these novel compounds as well as pharmaceutical and/or cosmetic compositions containing them.
    Type: Application
    Filed: July 25, 2011
    Publication date: September 4, 2014
    Applicant: Diverchim
    Inventors: Jean-Louis Brayer, Natacha Frison, Benoit Folleas
  • Publication number: 20140235592
    Abstract: The present invention relates to substituted 6-methoxy-4-amino-N-phenyl-2-naphtamides derivatives, processes for preparing them, pharmaceutical compositions to containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: February 19, 2014
    Publication date: August 21, 2014
    Applicant: Allergan, Inc.
    Inventors: Janet A. Takeuchi, Ling Li, Wha Bin Im
  • Publication number: 20140199601
    Abstract: The present invention aims to provide an additive for a non-aqueous electrolyte solution with excellent storage stability capable of forming a stable SEI on the surface of an electrode to improve cell performance such as a cycle performance, a discharge/charge capacity, and internal resistance, when the additive is used for electrical storage devices such as non-aqueous electrolyte solution secondary cells and electric double layer capacitors. The present invention also aims to provide a non-aqueous electrolyte solution containing the additive for a non-aqueous electrolyte solution and to provide an electrical storage device using the non-aqueous electrolyte solution.
    Type: Application
    Filed: July 6, 2012
    Publication date: July 17, 2014
    Applicant: SUMITOMO SEIKA CHEMICALS CO., LTD.
    Inventors: Tomohiro Onozuka, Shohei Fujimoto, Koji Fujita
  • Publication number: 20140194638
    Abstract: The present invention relates to a spirobenzylamine-phosphine, preparation method therefor and use thereof. The compound has a structure represented by formula (I), wherein n=0 to 3; R1, R2, R3, R4, R5, R6, R7, R8 and R9 having a value as defined in claim 1. Starting from the substituted 7-trifluoromesyloxy-7?-diarylphosphino-1,1?-spiro-dihydroindene, the compound is synthesized in a two-step or three-step reactions. The new spirobenzylamine-phosphine is complexed with an iridium precursor and is subjected to ion exchange, to give an Iridium/spirobenzylamine-phosphine complex comprising various anions. The spiro benzyl amine-phosphine/Iridium complex according to the present invention may be used for catalyzing asymmetry hydrogenation of a variety of alpha-substituted acrylic acids, has high activity and enantio-selectivity, and has a good prospect of industrialization.
    Type: Application
    Filed: July 27, 2012
    Publication date: July 10, 2014
    Applicant: ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD.
    Inventors: Qilin Zhou, Shoufei Zhu, Yanbo Yu, Kun Li, Lixin Wang
  • Publication number: 20140148415
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 29, 2014
    Applicant: NOVARTIS AG
    Inventors: Robert SCHMOUDER, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • Patent number: 8692022
    Abstract: The present invention relates to the field of catalytic hydrogenation and, more particularly, to the use of Ru complexes with bidentate ligands, having one amino or imino coordinating group and one phosphino coordinating group, in hydrogenation processes for the reduction of esters or lactones into the corresponding alcohol or diol respectively.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: April 8, 2014
    Assignee: Firmenich SA
    Inventors: Lionel Saudan, Philippe Dupau, Jean-Jacques Riedhauser, Patrick Wyss
  • Patent number: 8691718
    Abstract: The present invention provides a novel ligand represented by the following formula and a novel transition metal complex having the ligand, which shows superior enantioselectivity and catalytic efficiency, particularly high catalyst activity, in various asymmetric synthesis reactions. A transition metal complex having, as a ligand, a compound represented by the formula wherein R4 is a hydrogen atom or a C1-6 alkyl group optionally having substituent(s), and R5 and R6 are each a C1-6 alkyl group optionally having substituent(s), or the formula is a group represented by the formula wherein ring B is a 3- to 8-membered ring optionally having substituent(s).
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: April 8, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Mitsuhisa Yamano, Mitsutaka Goto, Shinji Kawaguchi, Masatoshi Yamada, Jun-ichi Kawakami
  • Publication number: 20140093880
    Abstract: A composition, a kit, and a method of isolating a vesicle from a sample using a compound comprising zwitterion moieties, which may be used to analyze vesicles, and proteins, glycoprotein, lipids, or nucleic acids thereof.
    Type: Application
    Filed: April 4, 2013
    Publication date: April 3, 2014
    Applicant: Samsung Electronics Co., Ltd.
    Inventors: Ga-hee KIM, Chang-eun YOO, Ye-ryoung YONG, Myo-yong LEE
  • Patent number: 8686154
    Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: April 1, 2014
    Assignee: Emisphere Technologies, Inc.
    Inventors: Donald J. Sarubbi, Eugene N. Barantsevitch
  • Patent number: 8685936
    Abstract: The invention relates to prodrugs of hydroxyl-substituted adamantane compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: April 1, 2014
    Assignee: Apogee Biotechnology Corporation
    Inventors: Charles D. Smith, Yan Zhuang, Lynn W. Maines
  • Publication number: 20140088303
    Abstract: Disclosed is a method for highly efficiently obtaining an optically active alcohol from a carbonyl compound highly enantioselectively. Also disclosed is a ligand used in such a method. Specifically, an optically active alcohol is obtained by reacting a carbonyl compound and an organozinc compound by using a ligand (L) shown below.
    Type: Application
    Filed: November 27, 2013
    Publication date: March 27, 2014
    Applicants: Sekisui Medical Co., Ltd., National University Corporation Nagoya University
    Inventors: Kazuaki ISHIHARA, Manabu HATANO, Takashi MIYAMOTO
  • Publication number: 20140066409
    Abstract: The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, particularly for use as an antibiotic.
    Type: Application
    Filed: December 13, 2011
    Publication date: March 6, 2014
    Applicants: UNIVERSITÄT KONSTANZ, RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN
    Inventors: Günter Mayer, Christina Elsbeth Luense, Valentin Wittmann, Magnus S. Schmidt
  • Publication number: 20140057877
    Abstract: This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicity of neurotoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan.
    Type: Application
    Filed: October 18, 2011
    Publication date: February 27, 2014
    Inventors: Michael A. Murphy, Mitchell R. Malachowski
  • Patent number: 8658825
    Abstract: The present application is directed to i) a method for synthesizing aminophosphine (P,N) and phosphine-aminophosphine (P,N,P) ligands, ii) the use of such ligands in the preparation of metal complexes as hydrogenation catalysts, and iii) aminophosphine (P,N) and phosphine-aminophosphine (P,N,P) ligands of various structures. In particular, the methods in i) involve reacting a protected tertiary amine of formula (I) with a metal phosphide of the formula Y—PR8R9 to afford an aminophosphine of formula (II), which can then be optionally further reacted with a phosphine of the formula (III) to afford the phosphine-aminophosphine of formula (IV).
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: February 25, 2014
    Assignee: Kanata Chemical Technologies Inc.
    Inventors: Kamaluddin Abdur-Rashid, Rongwei Guo, Xuanhua Chen, Wenli Jia
  • Publication number: 20140051870
    Abstract: Phosphenium compounds with the general formula I: in which R1, R2, R3 and R4 are identical or different and represent a linear or branched C1-C6-alkyl radical, which can optionally be substituted, or R1 and R2 and/or R3 and R4 are bonded to one another with the formation of a ring, R5 and R6 stand for a saturated or unsaturated and linear or branched alkyl group, alkenyl group or aryl group, which can have suitable substituents, even heteroatoms as substituents, or a heteroatom-comprising hydrocarbon group, which can have suitable substituents, and the R5 and R6 radicals can form a ring which can be 4- to 20-membered, saturated or unsaturated and alicyclic or heteroalicyclic and can exhibit suitable substituents, X? represents an anion, a process for the preparation thereof, and also the use of these compounds in metal complexes which can be used as catalysts in organic synthesis, are claimed.
    Type: Application
    Filed: February 23, 2012
    Publication date: February 20, 2014
    Inventors: Manuel Alcarazo, Hans Bruns, Jekaterina Petuskova
  • Publication number: 20140001056
    Abstract: The invention relates to a method of inhibiting the insertion of one or more membrane proteins into a lipid bilayer. The invention also relates to a method of inserting a pre-determined number of membrane proteins into a lipid bilayer and lipid bilayers having a pre-determined number of membrane proteins inserted therein. The lipid bilayers of the invention are useful as sensor arrays, particularly for sequencing nucleic acids.
    Type: Application
    Filed: January 11, 2012
    Publication date: January 2, 2014
    Applicant: ISIS INNOVATION LIMITED
    Inventors: John Hagan Pryce Bayley, Pinky Raychaudhuri
  • Patent number: 8609142
    Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: December 17, 2013
    Assignee: BIND Therapeutics, Inc.
    Inventors: Greg Troiano, Michael Figa, Abhimanyu Sabnis
  • Patent number: 8609721
    Abstract: The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or both, e.g., in a subject in need thereof, using a compound or formulation of the present invention. The present invention also relates to methods of treating a subject suffering from a chronic or acute disease, malady or condition due at least in part to an abnormality in the activity of an endogenous metabotropic glutamate receptor or a NAALADase enzyme or both, using a compound or formulation of the present invention.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: December 17, 2013
    Assignee: Georgetown University
    Inventors: Alan P. Kozikowski, Jarda T. Wroblewski, Fajun Nan
  • Publication number: 20130253185
    Abstract: The present invention provides novel compounds and ligands that are useful in transition metal catalyzed cross-coupling reactions. For example, the compounds and ligands of the present invention are useful in palladium or gold catalyzed cross-coupling reactions.
    Type: Application
    Filed: November 17, 2011
    Publication date: September 26, 2013
    Applicant: Dalhousie University
    Inventors: Rylan J. Lundgren, Mark Stradiotto
  • Patent number: 8536362
    Abstract: The present invention provides ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: September 17, 2013
    Assignee: Nucitec S.A. de C.V.
    Inventors: Ricardo Abraham De La Cruz Cordero, Miguel Ångel Duarte Vázquez, Jorge Luis Rosado Loria
  • Patent number: 8518913
    Abstract: The present invention relates to novel phosphorous derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: August 27, 2013
    Assignee: Allergan, Inc.
    Inventors: Haiqing Yuan, Richard I. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Publication number: 20130217916
    Abstract: The present invention describes tripodal catechol derivatives with an adamantyl basic framework for the functionalisation of surfaces, and methods for their production and use. A fourth remaining position of the adamantane skeleton is suitable to be optionally functionalised by so-called click reactions, for example with biomolecules, polyethylene glycol or active agents.
    Type: Application
    Filed: September 7, 2011
    Publication date: August 22, 2013
    Applicant: JÜSTUS-LIEBIG-UNIVERSITÄT GIESSEN
    Inventors: Wolfgang Maison, Elisa Franzmann, Faiza Khalil
  • Publication number: 20130216553
    Abstract: A method for detecting an inflammatory or an autoimmune condition, comprising analyzing bacterial lipids, such as phosphorylated dihydroceramides (PDHC), in a sample; and, comparing results of the analysis of the bacterial lipids in the sample with information on occurrence of the bacterial lipids in a comparable sample, wherein the comparison is indicative of the inflammatory or the autoimmune condition. An example of the autoimmune condition is multiple sclerosis. According to one embodiment, an increased ratio of phosphoglycerol dihydroceramide (PG DHC) to phosphoethanolamine dihydroceramide (PE DHC) in a blood sample indicates a presence of MS in the source patient. The use of PDHCs as biomarkers for detection of MS is described. Antibodies specific to PG DHC or PE DHC are also provided, along with their uses. Also provided are compositions comprising bacteria-originated lipids useful for modulation of immune responses or TLR pathways in humans, animals, and human or animal cells or tissues.
    Type: Application
    Filed: October 31, 2011
    Publication date: August 22, 2013
    Applicant: University of Connecticut
    Inventors: Robert B. Clark, Frank C. Nichols
  • Publication number: 20130193382
    Abstract: The present invention relates to compounds of the formula (I) and to the use thereof in electronic devices. The invention furthermore relates to electronic devices, preferably organic electroluminescent devices (OLEDs), comprising one or more com-pounds of the formula (I). The invention again furthermore relates to the preparation of compounds of the formula (I) and to formulations comprising one or more compounds of the formula (I).
    Type: Application
    Filed: September 6, 2011
    Publication date: August 1, 2013
    Applicant: MERCK PATENT GmbH
    Inventors: Arne Buesing, Thomas Eberle, Irina Martynova, Teresa Mujica-Fernaud
  • Publication number: 20130197228
    Abstract: The present invention relates to functionalised fluoroalkylfluorophosphate salts, in particular as ionic liquids, to the preparation thereof and to the use thereof.
    Type: Application
    Filed: August 30, 2011
    Publication date: August 1, 2013
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Berthold Theo Hoge, Anne Julia Bader, Nikolai Mykola Ignatyev, Michael Schulte, Wolfgang Hierse, Waldemar Wiebe, Helge Willner
  • Publication number: 20130158261
    Abstract: The present invention provides HIV protease inhibitors of formulas I, IA, IB, Ib or II, or pharmaceutically acceptable salts thereof, wherein R2 may be, for example, 2-pyridyl-CH2—, 3-pyridyl-CH2—, 4-pyridyl-CH2—, a sulfonyl group as described in the formulas herein including benzenesulfonyl or thiophenesulfonyl groups, R2a—CO)—, R2a being selected from the group consisting of piperonyl, 2-pyranzinyl (unsubstituted or substituted with H, or an alkyl of 1 to 4 carbon atoms) or a picolylamine group as described herein, wherein R3 may be, for example, a phenyl group or diphenylmethyl group as described herein, and wherein Cx may be, for example, COOH, CONR5R6, CH2OH or CH2OR7.
    Type: Application
    Filed: February 15, 2013
    Publication date: June 20, 2013
    Applicant: TaiMed Biologics, Inc.
    Inventor: TaiMed Biologics, Inc.
  • Patent number: 8410247
    Abstract: Water soluble reagents and methods for the formation of an amide bond between a phosphinothioester and an azide in an aqueous medium. The phosphinothioester is generated using a water-soluble phosphinothiol reagent. This reaction allows formation of an amide bond between a wide variety of chemical species including amino acids, peptides or protein fragments in an aqueous solution. Of particular interest, this reaction allows for the formation of an amide bond in a physiological setting. In a specific embodiment, this invention provides reagents and methods for peptide ligation in an aqueous medium. The reaction eliminates the need for a cysteine residue and is traceless leaving no residual atoms in the ligated peptide product.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: April 2, 2013
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Ronald T. Raines, Annie Tam, Matthew B. Soellner
  • Patent number: 8378100
    Abstract: The present invention provides ?-hydroxy phosphonate compounds that are autotaxin inhibitors.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: February 19, 2013
    Assignee: University of Virginia Patent Foundation
    Inventors: Kevin R. Lynch, Timothy L. Macdonald
  • Patent number: 8361993
    Abstract: The present invention relates to hydroxy-bisphosphonic acid derivatives corresponding to general formula (I): in which: -n and m denote, independently of one another, an integer ranging from 1 to 4, —X denotes an oxygen atom or an N—R3 group, —R1 and R3 denote, independently of one another, a linear or branched C1 to C6 alkyl group, and —R2 denotes a residue of a molecule of therapeutic or diagnostic interest, or pharmaceutically acceptable salts of said derivatives, and also the method for the preparation thereof and the therapeutic or diagnostic use thereof.
    Type: Grant
    Filed: January 5, 2009
    Date of Patent: January 29, 2013
    Assignees: Universite de Nantes, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Maxim Egorov, Yannick Fortun, Dominique Heymann, Jacques Lebreton, Monique Mathe, Marc Padrines, Francoise Redini
  • Patent number: 8343450
    Abstract: Methods and compositions to extract radionuclides such as various actinides and lanthanides from organic and/or aqueous solutions by utilizing extractant functionalized carbon nanotubes are disclosed. More particularly, phosphorous-containing (such as phosphine oxides, phosphoric acids or phosphates) organic extractants and other predesigned extractants (such as crown ethers, calncrown derivatives, malonamide and diglycolamide derivatives, polyethylene glycol derivatives, cobalt dicarbollide derivatives, and N-donating heterocyclic ligands) can be covalently and/or non-covalently employed on the surfaces and/or ends (tips) of carbon nanotubes for the purpose of removal radionuclides such as various actinides and lanthanides from organic and/or aqueous solutions. Extractant functionalized carbon nanotubes can be used for extracting radioactive nuclides from nuclear waste or spent nuclear fuel, which are produced and/or reprocessed from the nuclear power generation or other nuclear application.
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: January 1, 2013
    Assignee: Chemnano Materials, Ltd.
    Inventor: Pingshan Wang
  • Patent number: 8329676
    Abstract: The present invention provides sphingosine-1-phosphate analogs that are potent, and selective agonists at one or more S1P receptors, specifically the S1P1 receptor type, which alter lymphocyte trafficking. The compounds of the invention include compounds having a phosphate moiety as well as compounds with hydrolysis-resistant phosphate surrogates such as phosphonates, alpha-substituted phosphonates, and phosphothionates.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: December 11, 2012
    Assignee: University of Virginia Patent Foundation
    Inventors: Kevin R. Lynch, Timothy L. Macdonald
  • Patent number: 8309738
    Abstract: Methods for the preparation of indene-based thiazolidinethiones are provided comprising contacting 1-amino-2,3-dihydro-1H-inden-2-ol, or a substituted derivative thereof, with an acid under suitable reaction conditions to provide a first intermediate; and contacting the first intermediate with an alkali xanthate in the presence of an alkali hydroxide under suitable reaction conditions to provide a compound of formula (III), wherein R1-R8 are defined herein.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: November 13, 2012
    Assignee: University of Iowa Research Foundation
    Inventors: Horacio F. Olivo, Antonio Victor Osorio Lozada